Use of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy
Journal of the American Heart Association · 16.01.2024 · 13 (2)
DOI: 10.1161/jaha.123.030512 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 16.01.2024. Verfasst von An-Li Yu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Hereditary transthyretin amyloid cardiomyopathy (hATTR‐CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR‐CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium‐99m‐pyrophosphate in individuals diagnosed with hATTR‐CM. Methods and Results We retrospectively analyzed a prospective cohort from the NEURO‐TTRansform trial, including patients with hATTR‐CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR‐CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium‐99m‐pyrophosphate single‐photon emission computed tomography/computed tomography was conducted at baseline and during follow‐up. Thirteen patients with hATTR‐CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow‐up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979, P =0.028), whereas the control group showed no significant change (4.079 to 3.915, P =0.237). Patients receiving eplontersen demonstrated a significantly greater reduction in volumetric heart and lung ratio compared with the control group (−20.7% versus −3.4%, P =0.007).
Conclusions
The volumetric heart and lung ratio used to quantify technetium‐99m‐pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR‐CM. These findings suggest the potential efficacy of eplontersen in treating hATTR‐CM and highlight the value of technetium‐99m‐pyrophosphate single‐photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan.
- Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital Hsin-Chu Branch Hsinchu Taiwan.
- Department of Nuclear Medicine National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan.
- National Taiwan University College of Medicine Graduate Institute of Clinical Medicine Taipei Taiwan.
- Department of Medical Imaging National Taiwan University Hospital Taipei Taiwan.
- Department of Medical Imaging and Radiological Technology Yuanpei University of Medical Technology Hsinchu Taiwan.
ORCID-Profile: An-Li Yu, Cheng-Hsuan Tsai, Mao-Yuan Su, Chia-Tung Shun, Hsueh-Wen Hsueh, Jimmy Jyh-Ming Juang, Chia-Hua Hsu, Sung-Tsang Hsieh, Mei-Fang Cheng, Chi-Chao Chao, Yen-Hung Lin
Zitieren
APA
Yu, A. L., Chen, Y. C., Tsai, C. H., Wu, Y. A., Su, M. Y., Chou, C. H., Shun, C. T., Hsueh, H. W., Juang, J. J., Lee, M. J., Tseng, P. H., Hsu, C. H., Hsieh, S. T., Ko, C. L., Cheng, M. F., Chao, C. C., & Lin, Y. H. (2024). Use of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy. Journal of the American Heart Association, 13(2). https://doi.org/10.1161/jaha.123.030512
Vancouver
Yu AL, Chen YC, Tsai CH, Wu YA, Su MY, Chou CH, et al. Use of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy. Journal of the American Heart Association. 2024;13(2). doi:10.1161/jaha.123.030512
BibTeX
@article{Yu2024,
author = {Yu, An-Li and Chen, Yi-Chieh and Tsai, Cheng-Hsuan and Wu, Yuan-Kun Aden and Su, Mao-Yuan and Chou, Chia-Hung and Shun, Chia-Tung and Hsueh, Hsueh-Wen and Juang, Jimmy Jyh-Ming and Lee, Ming-Jen and Tseng, Ping-Huei and Hsu, Chia-Hua and Hsieh, Sung-Tsang and Ko, Chi-Lun and Cheng, Mei-Fang and Chao, Chi-Chao and Lin, Yen-Hung},
title = {Use of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy},
journal = {Journal of the American Heart Association},
year = {2024},
volume = {13},
number = {2},
doi = {10.1161/jaha.123.030512}
}
EUVIMED